The present aim of the study was to develop a Proniosomal gel in Transdermal patches system for Glipizide for the Treatment of Diabetics mellitus that is capable of efficiently delivering entrapped drug over an extended period of time. Glipizide is a second generation of sulfonylurea, it can accurately lowered the blood glucose level in humans by stimulating the release of insulin from the pancreases and is typically prescribed to treat type ll diabetics (non insulin dependent diabetic mellitus).The half life of Glipizide is (3.4±0.7 hours) necessitate it be administered in 2 or 3 doses of 2.5 to 10mg per day. Thus the development of controlledreleased dosage forms would clearly be advantageous.